Alexion Pharmaceuticals Profile

135.09
USD 0.56  0.41%
91%
49%

Exercise or conversion by Ann Veneman of 2725 shares of Alexion Pharmaceuticals subject to Rule 16b-3

Alexion Pharmaceuticals insider trading alert for exercise of common stock par value $.0001 per share by Ann Veneman, the corporate stakeholder, on July 19, 2018. This event was filed by Alexion Pharmaceuticals I with SEC on 2011-02-04. Statement of changes in beneficial ownership - SEC Form 4 [view details]   

Alexion Pharmaceuticals Summary

Alexion Pharmaceuticals (ALXN) is traded on BATS Exchange in USA. It is located in CONNECTICUT U.S.A and employs 2,525 people. Alexion Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification.The company currently falls under 'Large-Cap' category with current market capitalization of 30.23 B. Alexion Pharmaceuticals conducts business under Healthcare sector and is part of Biotechnology industry. This company has 222.5 M outstanding shares of which 3.99 M shares are presently shorted by private and institutional investors with about 3.36 trading days to cover. ALEXION PHARM INC currently holds about 1.61 B in cash with 830.05 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.22.
Check Alexion Pharmaceuticals Probability Of Bankruptcy

Ownership Allocation (%)

Target Price Odds Analysis

Odds Below 135.09HorizonTargetOdds Above 135.09
88.72%30 days 135.09 11.14%
Based on normal probability distribution, the odds of Alexion Pharmaceuticals to move above current price in 30 days from now is about 11.14% (This Alexion Pharmaceuticals probability density function shows the probability of Alexion Pharmaceuticals Stock to fall within a particular range of prices over 30 days) .

Top Holders

Major Institutional Holders

InstituionSecurity TypeTotal SharesValue
SwedbankCommon Shares820.9 K101.9 M
Bank Of MontrealCommon Shares669.3 K83.1 M
Calamos Advisors LlcCall Options61 K7.6 M
View Alexion Pharmaceuticals Diagnostics

Selected Alexion Pharmaceuticals Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

Key Fundamentals

Alexion Pharmaceuticals Against Markets

Current Ratings

Alexion Pharmaceuticals 30 Days Performance Scores
Risk Adjusted
Performance Score (0 to 100)
22 
Chance of
Financial Distress (0 to 100%)
8 
Equity ratings for Alexion Pharmaceuticals are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes various therapeutic products. The company was founded in 1992 and is headquartered in New Haven, Connecticut. Alexion Pharmaceuticals operates under Biotechnology classification in USA and traded on NASDAQ. It employs 2525 people. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
Alexion Pharmaceuticals SEC Filings
Alexion Pharmaceuticals SEC Filings
Security & Exchange Commission EDGAR ReportsView All
NameAlexion Pharmaceuticals
CEO, DirectorLudwig HantsonView All
Thematic Classification
Currently Active Investing Idea
  Biotech
View All
Analyst Consensus
Piotroski F Score
Macroaxis Advice
Specialization
Healthcare, Biotechnology
InstrumentUSA Stock View All
RegionNorth America
LocationCONNECTICUT U.S.A
Business Address100 College Street
Foreign Associate  Austria
ExchangeBATS Exchange
CIK Number0000899866
ISINUS0153511094
CUSIP015351109
SectorHealthcare
IndustryBiotechnology
BenchmarkDOW
Websitewww.alexion.com
Phone475 230 2596
CurrencyUSD - US Dollar

Alexion Pharmaceuticals Corporate Directors

Felix Baker Director, Ph.D
Andreas Rummelt Independent Director, Ph.D
Deborah Dunsire Independent Director
Check also Trending Equities. Please also try Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.